Pfizer, BioNTech see stock, hope soar as they say COVID-19 vax 90% effective, plot November EUA After Pfizer's vaccine data, analysts say COVID19 drugmakers face questions about long-term sales prospects These are the healthcare experts Biden named to his COVID-19 advisory board FDA greenlights first diagnostic test for COVID-19 antibodies that block the virus from entering cells Biopharma roundup: Fauci says Pfizer news bodes well for Moderna Oxford's rapid COVID-19 test acquired by Prenetics to screen airport passengers in London, Hong Kong Merlo: COVID-19 testing, return to work platform have 'expanded the universe' of CVS customers T-cell discovery points to potential strategy for managing chronic lung disease after COVID-19 Fierce Pharma Politics—Biden puts COVID-19 transition task force on the job Healthcare, tech companies are vying for a piece of back-to-work market. Here are the new opportunities post-COVID Stanford develops CRISPR 'lab on a chip' for detecting COVID-19 Featured Story | By Ben Adams Pfizer and German mRNA biotech partner BioNTech have released an early look at their experimental pandemic vaccine, and the news is good. read more |
| |
|---|
|
Top Stories By Eric Sagonowsky While much of the world focused on Pfizer and BioNTech’s positive COVID-19 vaccine news on Monday, analysts started gaming out potential ripple effects, namely for companies making coronavirus therapeutics. read more By Tina Reed Former U.S. Surgeon General Vivek Murthy and former Food and Drug Administration Commissioner David Kessler will be among public health leaders guiding the transition team for President-elect Joe Biden regarding COVID-19. Here's who else is in the lineup. read more By Conor Hale The diagnostic developed by GenScript is designed to provide a test result within one hour. read more By Eric Sagonowsky,Angus Liu,Kyle Blankenship,Conor Hale,Fraiser Kansteiner After Pfizer reported promising efficacy data for its coronavirus vaccine, experts and analysts started speculating about how other vaccine and therapeutics players might fare with their own programs. Moderna is in a strong position, they figured, while therapeutics makers face questions. read more By Conor Hale A low-cost, rapid coronavirus diagnostic developed by researchers at the University of Oxford is now in place to screen passengers at major international airports in London and Hong Kong. read more By Paige Minemyer CVS Health's programs to address COVID-19 have "expanded the universe of people" using its services, CEO Larry Merlo said on a call with investors on Friday. read more By Angus Liu Elderly survivors of COVID-19 and influenza are prone to long-term lung problems. A new study from the Mayo Clinic offers one possible explanation for why older people are more susceptible to lung inflammation and fibrosis following viral infection—and tissue-resident memory CD8+ T cells might be to blame. read more By Eric Sagonowsky President-elect Joe Biden unveiled his COVID-19 transition task force Monday, with Vivek Murthy, David Kessler and Marcella Nunez-Smith co-chairing—and some other bold-faced names in the infectious disease world serving on the panel. First order of business: Working with state and local officials to determine conditions around the country as case counts surge. read more By Heather Landi As employers, universities, and public venues look to safely bring people back into buildings, it has opened up a massive market opportunity for healthcare and tech players. Here is what employers are looking for and the long-term business impact for digital health companies. read more By Conor Hale Researchers at Stanford University have developed a CRISPR-based “lab on a chip” to detect COVID-19, and are working with automakers at Ford to develop their prototype into a market-ready product. read more |
